Pear Therapeutics Announces Formulary Availability for its Three FDA Authorized Prescription Digital Therapeutics at OptumRX

Pear Therapeutics, Inc. today announced formulary availability of its commercial products at OptumRx, Inc., the innovative pharmacy care services business of Optum, Inc. Pear’s commercial products include the Prescription Digital Therapeutics (PDTs) reSET® and reSET-O® for the treatment of substance use disorder and opioid use disorder, respectively, and Somryst® for the treatment of chronic insomnia. OptumRx will offer and administer standard pharmacy benefit coverage for reSET, reSET-O and Somryst for members who choose to add the products to their formularies.